Elevance Health (NYSE:ELV) delivered strong Q2 with ~$49.8B revenue, GAAP EPS $6.71 and adj. EPS $7.45, raised its 2026 adj. EPS guide to ≥$27 and set 2027 growth targets, while boosting buybacks/dividend and seeing analyst price-target increases as membership and CarelonRx scripts expand.
Previous Week Recap
- Elevance Health Revenue, EPS Guidance Raised: Elevance Health (ELV) Q2 revenue ~$49.8B, GAAP EPS $6.71, adjusted EPS $7.45. Raised 2026 adjusted EPS guide to ≥$27.00; 2027 target: ≥12% adj EPS growth. Buybacks $234M; dividend $1.72.
- ELV Health Benefits, Carelon Revenue: ELV Q2 2026: Health Benefits revenue $42.7B (+2.7% y/y); Carelon revenue $19.2B; medical membership ~44.9M; benefit expense ratio 89.7%; claims payable avg 45.4 days; CarelonRx 80.9M scripts.
- Analysts Raise Elevance Targets: Analysts updated Elevance Health (ELV) targets: TD Cowen raised target to $465, Leerink lifted target to $395; other brokers left ratings unchanged. Key trader fact: price targets moved higher.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.